Healthcare Services

Global Systemic Aspergillosis And Systemic Candidiasis Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities

April 7, 2026April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Systemic Aspergillosis And Systemic Candidiasis Market By The End Of 2030?

The systemic aspergillosis and systemic candidiasis market has experienced steady expansion in recent years. It is projected to climb from $7.57 billion in 2025 to $7.94 billion in 2026, showing a compound annual growth rate (CAGR) of 4.9%. This historical growth can be attributed to a growing number of immunocompromised patients, an increasing prevalence of invasive fungal infections, the accessibility of azole and amphotericin formulations, the enlargement of hospital intensive care units, and heightened diagnostic awareness.

The market for systemic aspergillosis and systemic candidiasis is projected to experience robust expansion over the coming years. This market is set to reach $9.76 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.3%. This anticipated growth is attributable to several factors, including the increasing development of novel antifungal agents, a heightened focus on antifungal resistance management, the expansion of targeted antifungal therapies, growing investments in infectious disease research, and the increasing adoption of combination treatment regimens. Key trends anticipated during the forecast period encompass the increasing adoption of advanced antifungal therapies, a growing emphasis on the early diagnosis of systemic fungal infections, the broader implementation of combination antifungal treatment approaches, rising demand for hospital-based critical care antifungals, and enhanced monitoring of drug resistance patterns.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp

What Primary Drivers Are Shaping The Development Of The Systemic Aspergillosis And Systemic Candidiasis Market?

The rising prevalence of fungal diseases is projected to boost the systemic aspergillosis and systemic candidiasis market going forward. Fungal diseases are defined as infections caused by fungi, capable of affecting various body parts and leading to diverse symptoms and complications. These conditions include cutaneous skin infections, respiratory infections, and systemic infections. Antifungal medications, such as oral azoles, voriconazole, and liposomal amphotericin B, are used to treat fungal diseases. For instance, in 2023, the UK Health Security Agency, a UK-based government agency, reported that the rate of yeast-related bloodstream infections across England increased by 4% when compared to 2022. Consequently, the escalating incidence of fungal disease is propelling the growth of the systemic aspergillosis and systemic candidiasis market.

Which Segment Classifications Shape The Systemic Aspergillosis And Systemic Candidiasis Market?

The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –

1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types

2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications

3) By End User: Clinic, Hospital, Other End Users

Subsegments:

1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole

2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection

3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis

4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines

5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents

Which Market Trends Are Creating New Opportunities In The Systemic Aspergillosis And Systemic Candidiasis Market?

Leading companies in the systemic aspergillosis and systemic candidiasis markets are focusing on developing advanced products, such as echinocandins, to boost treatment effectiveness and tackle the growing challenge of antifungal resistance. Echinocandins are a class of antifungal medications that inhibit the synthesis of β-glucan, a critical component of the fungal cell wall. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, and Melinta Therapeutics, a US-based biotechnology company, secured approval from the Food and Drug Administration (FDA), a US-based federal agency dedicated to protecting public health, for REZZAYO (rezafungin for injection). REZZAYO (rezafungin for injection) is a novel once-weekly echinocandin intended for the treatment of candidemia in adults with limited or no alternative treatment options. Its design prioritizes ease of administration, as REZZAYO’s once-weekly dosing regimen simplifies treatment and enhances the continuity of care for patients with invasive candidiasis. This offers particular benefits for individuals in hospital settings, where the effective management of such infections is vital.

Which Companies Are Expanding Their Footprint In The Systemic Aspergillosis And Systemic Candidiasis Market?

Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS

Read the full systemic aspergillosis and systemic candidiasis market report here:

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

How Does The Systemic Aspergillosis And Systemic Candidiasis Market Perform Across Major Global Regions?

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Systemic Aspergillosis And Systemic Candidiasis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12148&type=smp

Browse Through More Reports Similar to the Global Systemic Aspergillosis And Systemic Candidiasis Market 2026, By The Business Research Company

Aspergillosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report

Candidiasis Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Invasive Fungal Infections Global Market Report

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795